10X Historical Cash Flow
| TXG Stock | USD 15.90 0.42 2.71% |
Analysis of 10X Genomics cash flow over time is an excellent tool to project 10X Genomics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Stock Based Compensation of 175.3 M or Change In Working Capital of 18.2 M as it is a great indicator of 10X Genomics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining 10X Genomics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether 10X Genomics is a good buy for the upcoming year.
10X |
About 10X Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in 10X balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which 10X's non-liquid assets can be easily converted into cash.
10X Genomics Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by 10X Genomics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of 10X Genomics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from 10X Genomics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into 10X Genomics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in 10X Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.At this time, 10X Genomics' Change In Cash is most likely to increase significantly in the upcoming years. The 10X Genomics' current Stock Based Compensation is estimated to increase to about 175.3 M, while Change Receivables is projected to decrease to (17.9 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Other Non Cash Items | 79K | 2.0M | 12.0M | 11.4M | Depreciation | 28.3M | 33.0M | 43.6M | 21.9M |
10X Genomics cash flow statement Correlations
Click cells to compare fundamentals
10X Genomics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
10X Genomics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (6.7M) | (14.6M) | (30.1M) | (21.2M) | 7.9M | 8.3M | |
| Investments | (42.8M) | (38.4M) | (106.7M) | (350.9M) | 87.2M | 91.6M | |
| Change In Cash | 406.4M | 212.2M | (92.6M) | (368.7M) | 131.9M | 138.5M | |
| Stock Based Compensation | 13.3M | 48.6M | 96.0M | 136.8M | 167.0M | 175.3M | |
| Free Cash Flow | (8.1M) | (256.3M) | (122.7M) | (165.3M) | (64.7M) | (68.0M) | |
| Change In Working Capital | 44.8M | (50.4M) | (87.4M) | (39.4M) | 17.3M | 18.2M | |
| Begin Period Cash Flow | 70.1M | 476.5M | 688.6M | 596.1M | 227.4M | 337.6M | |
| Total Cashflows From Investing Activities | (42.8M) | (38.4M) | (106.7M) | (350.9M) | (315.8M) | (300.0M) | |
| Other Cashflows From Financing Activities | 14.8M | 23.7M | 35.3M | 15.8M | 13.7M | 26.1M | |
| Depreciation | 7.1M | 19.0M | 28.3M | 33.0M | 43.6M | 21.9M | |
| Other Non Cash Items | 101K | 306.0M | 79K | 2.0M | 12.0M | 11.4M | |
| Capital Expenditures | 42.8M | 38.4M | 101.3M | 131.7M | 49.5M | 58.8M | |
| Total Cash From Operating Activities | 34.6M | (217.9M) | (21.4M) | (33.6M) | (15.2M) | (16.0M) | |
| Change To Account Receivables | (5.3M) | (17.8M) | (34.0M) | (18.9M) | (10.6M) | (11.1M) | |
| Change To Operating Activities | 51.2M | (12.2M) | (35.9M) | (8.5M) | (7.6M) | (7.3M) | |
| Net Income | (31.3M) | (542.7M) | (58.2M) | (166M) | (255.1M) | (267.9M) | |
| Total Cash From Financing Activities | 414.6M | 468.9M | 35.3M | 15.8M | 13.7M | 13.0M | |
| End Period Cash Flow | 476.5M | 688.6M | 596.1M | 227.4M | 359.3M | 387.5M | |
| Change To Netincome | 13.9M | 356.2M | 96.0M | 137.9M | 158.6M | 111.7M | |
| Change To Liabilities | 5.5M | 17.3M | 21.8M | 7.4M | 8.5M | 11.1M |
Currently Active Assets on Macroaxis
When determining whether 10X Genomics is a strong investment it is important to analyze 10X Genomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact 10X Genomics' future performance. For an informed investment choice regarding 10X Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in 10X Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 10X Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 5.261 | Quarterly Revenue Growth (0.01) | Return On Assets (0.11) | Return On Equity (0.25) |
The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 10X Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 10X Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.